Over the past two decades, the arsenal of disease-modifying therapies for multiple sclerosis (MS) has expanded considerably. This applies in particular to the relapsing-remitting form (RRMS), but the treatment options for the other subtypes have also improved. The evidence base for what is currently the only immunomodulatory therapy for primary chronic progressive MS (PPMS) has recently been expanded by several new studies.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Study report
Digital patient education for atrial fibrillation shows measurable effects
- Important basics and studies on cancer and the psyche
Interplay between cancer and mental illness
- IBDmatters - Synergy effects for IBD pathways
How combination therapies lead to better treatment results
- "Patients W.A.I.T. Indicator"
Access to new drugs is becoming increasingly difficult
- Cardiometabolic research
The liver-heart axis in the pathogenesis of cardiometabolic diseases
- ASCO 2025
Supportive therapies for greater adherence and compliance
- Heart rhythm
From harmonious symphony to age-related dissonance
- Precision therapy